Skip to main content

Table 4 Adjusted multivariate survival analyses

From: P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms

Comparison of staining

p53

SSTR-2a

CgA

HR (CI)

p

HR (CI)

p

HR (CI)

p

All 3 categories without dichotomisation

1.26 (0.99–1.60)

0.07

0.91 (0.72–1.15)

0.41

0.89 (0.69–1.15)

0.38

A: Neg (vs. het-pos)

1.88 (1.01–3.49)

0.05*

1.18 (0.61–2.29)

0.63

2.11 (1.15–3.88)

0.02*

B: Het-pos (vs. pos)

0.33 (0.19–0.60)

< 0.001*

1.18 (0.54–2.58)

0.68

1.13 (0.68–1.87)

0.63

C: Pos (vs. neg)

1.30 (0.83–2.04)

0.25

0.84 (0.52–1.35)

0.47

0.78 (0.47–1.30)

0.34

D: Neg (vs. het-pos + pos)

1.03 (0.67–1.58)

0.88

1.19 (0.78–1.82)

0.41

1.39 (0.89–2.18)

0.15

E: Het-pos (vs. neg + pos)

0.45 (0.27–0.75)

0.002*

1.08 (0.57–2.04)

0.82

1.31 (0.84–2.04)

0.23

F: Pos (vs. het-pos + neg)

1.85 (1.24–2.76)

0.003*

0.84 (0.53–1.34)

0.47

0.97 (0.65–1.47)

0.89

  1. Adjusted for age (> 65 years), gender, grade of differentiation (well- vs. poorly differentiated), primary tumour (pancreas vs. other primary tumours), tumour burden (locoregional disease vs. disseminated), performance status (PS > 2), and treatment (surgery or chemotherapy). The immune-staining outside the parenthesis in the column “Comparison of staining” indicated which score the HR relates to. *Indicates significant p-values < 0.05. Unadjusted HR (CI) and p-values are presented in Fig. 4, and were significant for p53 in the A and B comparison in the univariate analyses